Log In
BCIQ
Print this Print this
 

P-1055

  Manage Alerts
Collapse Summary General Information
Company Parion Sciences Inc.
DescriptionEpithelial sodium channel (ENaC) inhibitor
Molecular Target Epithelial sodium channel (ENaC)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard IndicationCystic fibrosis (CF)
Indication DetailsTreat cystic fibrosis (CF)
Regulatory Designation
PartnerVertex Pharmaceuticals Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$1,170.0M

$80.0M

$1,090.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/04/2015

$1,170.0M

$80.0M

$1,090.0M

Get a free BioCentury trial today